{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:46:36Z","timestamp":1787996796693,"version":"build-2784847793"},"reference-count":64,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Bispecific antibodies (BsABs) have become a new standard of treatment of refractory\/relapsed patients with diffuse large B-cell lymphoma and follicular lymphoma, being also intensively studied in other types of B-cell non-Hodgkin lymphoma (B-NHL). Since the therapy with BsABs results in profound B-cell depletion and T-cell exhaustion, it is associated with significantly increased risk of infections. Additional risk factors involve immune disorders caused by lymphoma itself and previous lines of therapy. In this review, we focus on the infectious complications in B-NHL patients treated BsABs, presenting their incidence in clinical trials, admittedly performed to a large extent during the COVID-19 pandemic, as well as the proposals of infection prophylaxis.<\/jats:p>","DOI":"10.3390\/cancers17152426","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T15:00:42Z","timestamp":1753196442000},"page":"2426","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Infectious Complications in Patients with B-Cell Non-Hodgkin Lymphoma Treated with Bispecific Antibodies"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8347-7557","authenticated-orcid":false,"given":"Agnieszka","family":"Szymczyk","sequence":"first","affiliation":[{"name":"Department of Hematology, National Medical Institute of the Ministry of Interior and Administration, Wo\u0142oska 137 Str., 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4562-6264","authenticated-orcid":false,"given":"Joanna","family":"Drozd-Soko\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Stefana Banacha 1 A Str., 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Hus","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Medical Institute of the Ministry of Interior and Administration, Wo\u0142oska 137 Str., 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Omer, M.H., Shafqat, A., Ahmad, O., Alkattan, K., Yaqinuddin, A., and Damlaj, M. (2023). Bispecific Antibodies in Hematological Malignancies: A Scoping Review. Cancers, 15.","DOI":"10.3390\/cancers15184550"},{"key":"ref_2","unstructured":"(2025, June 23). ISCT Leads Global Scientific Consortia to Respond to Recent FDA Report on Risk of T-Cell Malignancy in Patients Following CAR T-Cell Immunotherapies. Available online: https:\/\/www.isctglobal.org\/telegrafthub\/blogs\/lauren-reville\/2024\/01\/09\/isct-leads-global-scientific-consortia-to-respond-."},{"key":"ref_3","first-page":"2021-2-4","article-title":"Bispecific Antibodies for Non-Hodgkin\u2019s Lymphomas and Multiple Myeloma","volume":"10","author":"Chavez","year":"2021","journal-title":"Drugs Context"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Tavarozzi, R., and Manzato, E. (2022). The Role of Bispecific Antibodies in Non-Hodgkin\u2019s Lymphoma: From Structure to Prospective Clinical Use. Antibodies, 11.","DOI":"10.3390\/antib11010016"},{"key":"ref_5","unstructured":"FDA (2024). FDA Grants Accelerated Approval to Tarlatamab-Dlle for Extensive Stage Small Cell Lung Cancer, FDA."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-024-00989-w","article-title":"Bi- and Tri-Specific Antibodies in Non-Hodgkin Lymphoma: Current Data and Perspectives","volume":"14","author":"Dulery","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_7","first-page":"1472","article-title":"Bispecific Antibodies in Follicular Lymphoma","volume":"110","author":"Nizamuddin","year":"2024","journal-title":"Haematologica"},{"key":"ref_8","first-page":"100319","article-title":"Current and Emerging Monoclonal Antibodies, Antibody-Drug Conjugates, and Bispecific Antibodies in Treatment of Lymphoma","volume":"17","author":"Robertson","year":"2022","journal-title":"Leuk. Res. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T Cells to Hematological Malignancies with Bispecific Antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific Antibodies for the Treatment of B-Cell Lymphoma: Promises, Unknowns, and Opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lejeune, M., K\u00f6se, M.C., Duray, E., Einsele, H., Beguin, Y., and Caers, J. (2020). Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00762"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and Trispecific Immune Cell Engagers for Immunotherapy of Hematological Malignancies","volume":"16","author":"Sanz","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Radhakrishnan, V.S., and Davies, A.J. (2024). Bispecific Antibodies in Indolent B-Cell Lymphomas. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1295599"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with Polatuzumab Vedotin in Relapsed or Refractory Aggressive Large B Cell Lymphoma: A Phase 1b\/2 Trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE NHL-1): A Phase 2 Cohort of a Single-Arm, Multicentre Study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus Gemcitabine and Oxaliplatin (GemOx) versus Rituximab-GemOx for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (STARGLO): A Global Phase 3, Randomised, Open-Label Trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to Watch in 2023","volume":"15","author":"Kaplon","year":"2022","journal-title":"mAbs"},{"key":"ref_20","unstructured":"ClinicalTrials.Gov (2025, April 29). Home, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2023-173677","article-title":"Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma (R\/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial","volume":"142","author":"Korfi","year":"2023","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2024-200096","article-title":"Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r\/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072","volume":"144","author":"Hutchings","year":"2024","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e433516","DOI":"10.1200\/EDBK_433516","article-title":"Bispecific Antibody Use in Patients with Lymphoma and Multiple Myeloma","volume":"44","author":"Braun","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Salvaris, R., Ong, J., and Gregory, G.P. (2021). Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050355"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bangolo, A., Amoozgar, B., Mansour, C., Zhang, L., Gill, S., Ip, A., and Cho, C. (2025). Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies. Cancers, 17.","DOI":"10.3390\/cancers17020282"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Dabkowska, A., Domka, K., and Firczuk, M. (2024). Advancements in Cancer Immunotherapies Targeting CD20: From Pioneering Monoclonal Antibodies to Chimeric Antigen Receptor-Modified T Cells. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1363102"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus Recommendations on the Management of Toxicity Associated with CD3\u00d7CD20 Bispecific Antibody Therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/SPC.0000000000000699","article-title":"Supportive Care Measures for Bispecific T-Cell Engager Therapies in Haematological Malignancies","volume":"18","author":"Chen","year":"2024","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.19668","article-title":"Mitigating Infection Risks: The Promise and Challenge of Bispecific Antibodies in Haematological Malignancies","volume":"205","author":"Rafei","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.ymthe.2025.03.048","article-title":"Non-Relapse Mortality with Bispecific Antibodies: A Systematic Review and Meta-Analysis in Lymphoma and Multiple Myeloma","volume":"33","author":"Tix","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clml.2023.12.005","article-title":"Mosunetuzumab Safety Profile in Patients with Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I\/II Trial","volume":"24","author":"Matasar","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable Responses with Mosunetuzumab in Relapsed\/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I\/II Study","volume":"42","author":"Budde","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-Term 3-Year Follow-up of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma after \u22652 Prior Therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/jjco\/hyad082","article-title":"Dose-Escalation Part of Phase I Study of Single-Agent Mosunetuzumab in Japanese Patients with Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma","volume":"53","author":"Munakata","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in Combination with CHOP in Previously Untreated DLBCL: Safety and Efficacy Results from a Phase 2 Study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell\u2013Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in Relapsed\/Refractory Large B-Cell Lymphoma: 2-Year Follow-up from the Pivotal EPCORE NHL-1 Trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.1200\/JCO.2024.42.16_suppl.7032","article-title":"Epcoritamab + R-DHAX\/C in Transplant-Eligible Patients (Pts) with High-Risk Relapsed or Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"42","author":"Karimi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1016\/j.jtct.2023.12.500","article-title":"Results from the Epcore NHL-2 Trial Arm 8: Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP","volume":"30","author":"Vermaat","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood.2024026830","article-title":"Epcoritamab plus GemOx in Transplant-Ineligible Relapsed\/Refractory DLBCL: Results from the EPCORE NHL-2 Trial","volume":"145","author":"Brody","year":"2025","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7014","DOI":"10.1200\/JCO.2024.42.16_suppl.7014","article-title":"Epcoritamab with Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance in FL: EPCORE NHL-2 Arms 6 and 7","volume":"42","author":"Lori","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e5547136","DOI":"10.1097\/01.HS9.0000967800.55471.36","article-title":"S222: Epcoritamab with rituximab + lenalidomide (r2) provides durable responses in patients with high-risk follicular lymphoma, regardless of pod24 status","volume":"7","author":"Sureda","year":"2023","journal-title":"HemaSphere"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood-2024-200262","article-title":"Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial","volume":"144","author":"Falchi","year":"2024","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a Human CD20\u00d7CD3 Bispecific Antibody in Patients with CD20-Positive B-Cell Malignancies (ELM-1): Results from the Relapsed or Refractory Non-Hodgkin Lymphoma Cohort in a Single-Arm, Multicentre, Phase 1 Trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2024027044","article-title":"Odronextamab Monotherapy in R\/R DLBCL after Progression with CAR T-Cell Therapy: Primary Analysis of the ELM-1 Study","volume":"145","author":"Topp","year":"2025","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab Monotherapy in Patients with Relapsed\/Refractory Diffuse Large B Cell Lymphoma: Primary Efficacy and Safety Analysis in Phase 2 ELM-2 Trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and Efficacy of Odronextamab in Patients with Relapsed or Refractory Follicular Lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1182\/blood-2022-159586","article-title":"A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma: Recommended Dose Safety\/Efficacy Update and Escalation Exposure-Response Analysis","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood-2023-188444","article-title":"GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20\/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety\/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma","volume":"142","author":"Song","year":"2023","journal-title":"Blood"},{"key":"ref_51","unstructured":"Morschhauser, F. (2025, April 30). Englumafusp Alfa (CD19\/4-1BBL) Combined with Glofitamab Is Safe and Shows High Efficacy in Patients with R\/R Aggressive B-NHL: Final Results of the Dose Escalation Part of Phase 1 Trial BP41072. Available online: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422341\/franck.morschhauser.englumafusp.alfa.28cd19.4-1bbl29.combined.with.glofitamab.is.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29171%2Amarker%3D5099%2Afeatured%3D18527."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, Prophylaxis, and Treatment of Infections in Patients with MM Receiving Bispecific Antibody Therapy: Consensus Recommendations from an Expert Panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM-3 Trial Results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and Activity of Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma (MonumenTAL-1): A Multicentre, Open-Label, Phase 1-2 Study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Leblay, N., Maity, R., Hasan, F., and Neri, P. (2020). Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights into Mechanisms and Therapeutic Opportunities. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00636"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.2023023419","article-title":"CAR T Cells vs Bispecific Antibody as Third- or Later-Line Large B-Cell Lymphoma Therapy: A Meta-Analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in Patients with Lymphoma Treated with Bispecific Antibodies: A Systematic Review and Meta-Analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv."},{"key":"ref_61","first-page":"1483","article-title":"New Bispecific Antibodies in Diffuse Large B-Cell Lymphoma","volume":"110","author":"Minson","year":"2025","journal-title":"Haematologica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific Antibody Therapy, Its Use and Risks for Infection: Bridging the Knowledge Gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev."},{"key":"ref_63","unstructured":"(2025, April 30). Bacterial: Febrile Neutropenia\u2014Duration of Therapy\u2014New Drugs. Available online: https:\/\/www.ecil-leukaemia.com\/images\/ecil-10\/ECIL_10_-_bacterial_group_final_recommendations.pdf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","article-title":"Primary Antifungal Prophylaxis in Hematological Malignancies. Updated Clinical Practice Guidelines by the European Conference on Infections in Leukemia (ECIL)","volume":"39","author":"Pagano","year":"2025","journal-title":"Leukemia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/15\/2426\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:14:06Z","timestamp":1760033646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/15\/2426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":64,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cancers17152426"],"URL":"https:\/\/doi.org\/10.3390\/cancers17152426","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}